Marinus Pharmaceuticals to Present at the 2024 Cantor Global Healthcare Conference

9/10/24 8:00:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $MRNS alert in real time by email

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that management will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Thursday, September 19, 2024, at 10:20 a.m. ET.

A link to the event can be accessed on the Investors and Media page of Marinus' website at ir.marinuspharma.com/events-and-presentations. A replay of the webcast will be available approximately two hours after the completion of the event and will be archived for up to 90 days.

About Marinus Pharmaceuticals

Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company's product, ZTALMY^® (ganaxolone) oral suspension CV, is an FDA-approved prescription medication introduced in the U.S. in 2022. For more information, please visit www.marinuspharma.com and follow us on Facebook, LinkedIn and X.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240910315715/en/

Get the next $MRNS alert in real time by email

Date	Price Target	Rating	Analyst
9/23/2024	$6.00	Perform → Outperform	Oppenheimer
8/14/2024		Buy → Neutral	Ladenburg Thalmann
4/16/2024	$20.00 → $2.00	Outperform → Neutral	Robert W. Baird
4/15/2024	$24.00 → $3.00	Outperform → Sector Perform	RBC Capital Mkts
8/11/2023	$14.00 → $9.00	Outperform → Perform	Oppenheimer
1/20/2023	$23.00	Outperform	RBC Capital Mkts
12/20/2021	$32.00 → $30.00	Outperform	SVB Leerink

Marinus Pharmaceuticals to Present at the 2024 Cantor Global Healthcare Conference

Chat with this insight

Recent Analyst Ratings for
$MRNS

$MRNS
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Marinus Pharmaceuticals upgraded by Oppenheimer with a new price target

Marinus Pharmaceuticals downgraded by Ladenburg Thalmann

Marinus Pharmaceuticals downgraded by Robert W. Baird with a new price target

$MRNS
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Ezickson Elan returned $5,995 worth of shares to the company (10,900 units at $0.55), closing all direct ownership in the company (SEC Form 4)

Director Fischer Seth H. Z. returned $8,254 worth of shares to the company (15,007 units at $0.55), closing all direct ownership in the company (SEC Form 4)

CHIEF MEDICAL OFFICER Hulihan Joseph returned $39,999 worth of shares to the company (72,725 units at $0.55), closing all direct ownership in the company (SEC Form 4)

$MRNS
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

CHAIRMAN AND CEO Braunstein Scott bought $6,526 worth of shares (5,933 units at $1.10) and returned $167,530 worth of shares to the company (304,600 units at $0.55), closing all direct ownership in the company (SEC Form 4)

$MRNS
SEC Filings

SEC Form 15-12G filed by Marinus Pharmaceuticals Inc.

Amendment: SEC Form SCHEDULE 13G/A filed by Marinus Pharmaceuticals Inc.

SEC Form EFFECT filed by Marinus Pharmaceuticals Inc.

$MRNS
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Marinus Pharmaceuticals Inc.

SEC Form SC 13G filed by Marinus Pharmaceuticals Inc.

Amendment: SEC Form SC 13G/A filed by Marinus Pharmaceuticals Inc.

$MRNS
Leadership Updates

Live Leadership Updates

DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer

Marinus Pharmaceuticals Further Strengthens Board of Directors with Appointment of Sarah Noonberg, M.D., Ph.D.

Marinus Pharmaceuticals Appoints Marvin H. Johnson, Jr. to its Board of Directors

$MRNS
Press Releases

Fastest customizable press release news feed in the world

Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results

Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives

$MRNS
Financials

Live finance-specific insights

Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results

Ligand Reports Second Quarter 2024 Financial Results

Marinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2024 Financial Results on August 13, 2024

Marinus Pharmaceuticals to Present at the 2024 Cantor Global Healthcare Conference

Chat with this insight

Recent Analyst Ratings for $MRNS

$MRNS Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Marinus Pharmaceuticals upgraded by Oppenheimer with a new price target

Marinus Pharmaceuticals downgraded by Ladenburg Thalmann

Marinus Pharmaceuticals downgraded by Robert W. Baird with a new price target

$MRNS Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Ezickson Elan returned $5,995 worth of shares to the company (10,900 units at $0.55), closing all direct ownership in the company (SEC Form 4)

Director Fischer Seth H. Z. returned $8,254 worth of shares to the company (15,007 units at $0.55), closing all direct ownership in the company (SEC Form 4)

CHIEF MEDICAL OFFICER Hulihan Joseph returned $39,999 worth of shares to the company (72,725 units at $0.55), closing all direct ownership in the company (SEC Form 4)

$MRNS Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

CHAIRMAN AND CEO Braunstein Scott bought $6,526 worth of shares (5,933 units at $1.10) and returned $167,530 worth of shares to the company (304,600 units at $0.55), closing all direct ownership in the company (SEC Form 4)

$MRNS SEC Filings

SEC Form 15-12G filed by Marinus Pharmaceuticals Inc.

Amendment: SEC Form SCHEDULE 13G/A filed by Marinus Pharmaceuticals Inc.

SEC Form EFFECT filed by Marinus Pharmaceuticals Inc.

$MRNS Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Marinus Pharmaceuticals Inc.

SEC Form SC 13G filed by Marinus Pharmaceuticals Inc.

Amendment: SEC Form SC 13G/A filed by Marinus Pharmaceuticals Inc.

$MRNS Leadership Updates

Live Leadership Updates

DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer

Marinus Pharmaceuticals Further Strengthens Board of Directors with Appointment of Sarah Noonberg, M.D., Ph.D.

Marinus Pharmaceuticals Appoints Marvin H. Johnson, Jr. to its Board of Directors

$MRNS Press Releases

Fastest customizable press release news feed in the world

Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results

Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives

$MRNS Financials

Live finance-specific insights

Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results

Ligand Reports Second Quarter 2024 Financial Results

Marinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2024 Financial Results on August 13, 2024

Recent Analyst Ratings for
$MRNS

$MRNS
Analyst Ratings

$MRNS
Insider Trading

$MRNS
Insider Purchases

$MRNS
SEC Filings

$MRNS
Large Ownership Changes

$MRNS
Leadership Updates

$MRNS
Press Releases

$MRNS
Financials